0JXZ Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €23.26 |
52 Week High | €40.31 |
52 Week Low | €23.02 |
Beta | 0.058 |
11 Month Change | -7.31% |
3 Month Change | -20.39% |
1 Year Change | -37.80% |
33 Year Change | -59.74% |
5 Year Change | -81.84% |
Change since IPO | 263.44% |
Recent News & Updates
Recent updates
Shareholder Returns
0JXZ | GB Biotechs | GB Market | |
---|---|---|---|
7D | -0.6% | 4.3% | 0.8% |
1Y | -37.8% | -21.1% | 10.8% |
Return vs Industry: 0JXZ underperformed the UK Biotechs industry which returned -21.1% over the past year.
Return vs Market: 0JXZ underperformed the UK Market which returned 10.8% over the past year.
Price Volatility
0JXZ volatility | |
---|---|
0JXZ Average Weekly Movement | 2.5% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.6% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JXZ's share price has been volatile over the past 3 months.
Volatility Over Time: 0JXZ's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
0JXZ fundamental statistics | |
---|---|
Market cap | €1.53b |
Earnings (TTM) | €30.71m |
Revenue (TTM) | €243.58m |
49.9x
P/E Ratio6.3x
P/S RatioIs 0JXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0JXZ income statement (TTM) | |
---|---|
Revenue | €243.58m |
Cost of Revenue | €262.90m |
Gross Profit | -€19.31m |
Other Expenses | -€50.02m |
Earnings | €30.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 0.47 |
Gross Margin | -7.93% |
Net Profit Margin | 12.61% |
Debt/Equity Ratio | 0% |
How did 0JXZ perform over the long term?
See historical performance and comparison